Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics

被引:14
|
作者
Kim, Tae Hwan [1 ]
Bulitta, Jurgen B. [2 ]
Kim, Do-Hyung [3 ]
Shin, Soyoung [4 ]
Shin, Beom Soo [5 ]
机构
[1] Daegu Catholic Univ, Coll Pharm, Gyongsan 38430, Gyeongbuk, South Korea
[2] Univ Florida, Coll Pharm, Orlando, FL 32827 USA
[3] KNOTUS Co Ltd, Res Ctr, Guri 11910, Gyeonggi, South Korea
[4] Wonkwang Univ, Coll Pharm, 460 Iksan Daero, Iksan 54538, Jeonbuk, South Korea
[5] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Extended-release formulation; In vitro-in vivo correlation; Population pharmacokinetic model; Hydroxypropyl methylcellulose; Baclofen; INTESTINAL-ABSORPTION; POPULATION; TRANSPORT; MECHANISM; TABLETS; DESIGN; TIME;
D O I
10.1016/j.ijpharm.2018.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro-in vivo correlation (IVIVC), a predictive mathematical model between the in vitro dissolution and the in vivo pharmacokinetics has been utilized for the development of new extended release (ER) formulations. The aim of the present study was to extend the IVIVC approach, which correlates among the formulation composition, the in vitro dissolution, and the plasma drug concentration, to predict plasma drug concentrations from a given composition of the formulation, and vice versa, using baclofen as a model drug. Baclofen ER tablets with different dissolution rates were prepared by varying the composition of hydroxypropyl methylcellulose (HPMC). First, the HPMC compositions and the corresponding in vitro dissolutions parameters were correlated, and then the in vitro dissolution parameters were correlated with the in vivo dissolution parameters extracted from the pharmacokinetic profiles of the baclofen ER formulations via population pharmacokinetic modeling. The final extended IVIVC model linked the composition of the formulation, the in vitro dissolution, and the in vivo plasma concentration profile and was successfully applied for the prediction of in vivo pharmacokinetics from the amount of HPMC in baclofen ER formulations. The present approach holds great promise for designing optimal compositions of ER formulations to present desired plasma concentration profile.
引用
收藏
页码:276 / 286
页数:11
相关论文
共 50 条
  • [21] Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data
    Rajendar K. Mittapalli
    Patrick Marroum
    Yihong Qiu
    Kathleen Apfelbaum
    Hao Xiong
    Pharmaceutical Research, 2017, 34 : 1527 - 1533
  • [22] Extended release dosage form of glipizide:: Development and validation of a level A in vitro-in vivo correlation
    Ghosh, Animesh
    Bhaumik, Uttam Kumar
    Bose, Anirbandeep
    Mandal, Uttam
    Gowda, Veeran
    Chatterjee, Bappaditya
    Chakrabarty, Uday Sankar
    Pal, Tapan Kumar
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (10) : 1946 - 1951
  • [23] Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate
    Goncalves de Lima, L.
    Rossi de Campos, D.
    DRUG RESEARCH, 2016, 66 (05) : 225 - 229
  • [24] In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets
    da Silva, Jessica Domingos
    de Sousa, Valeria Pereira
    Cabral, Lucio Mendes
    Davanco, Marcelo Gomes
    Meulman, Jessica
    Carvalho, Patricia de Oliveira
    Campos, Daniel Rossi
    AAPS PHARMSCITECH, 2020, 21 (05)
  • [25] INVESTIGATION OF THE FOOD EFFECT ON THE IN VITRO-IN VIVO CORRELATION OF EXTENDED RELEASE FORMULATIONS: PALIPERIDONE CASE EXAMPLE.
    Kim, C.
    Muniz, P.
    Rodriguez, M.
    Cristofoletti, R.
    van Os, S.
    Subhani, S.
    Schmidt, S.
    Vozmediano, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S72 - S72
  • [26] Development of a Dissolution Test for Extended-Release Bromopride Pellets with In Vivo-In Vitro Correlation
    da Silva, Marcos Giovani R.
    Volpato, Nadia Maria
    Pinto, Eduardo C.
    Cabral, Lucio M.
    de Sousa, Valeria P.
    DISSOLUTION TECHNOLOGIES, 2015, 22 (02): : 24 - 33
  • [27] A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations
    Fotaki, N.
    Aivaliotis, A.
    Butler, J.
    Dressman, J.
    Fischbach, M.
    Hempenstall, J.
    Klein, S.
    Reppas, C.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 73 (01) : 115 - 120
  • [28] Development and In Vitro-In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease
    Zhang, Chi
    Shao, Huihui
    Han, Zunsheng
    Liu, Bo
    Feng, Jing
    Zhang, Jie
    Zhang, Wenxuan
    Zhang, Kun
    Yang, Qingyun
    Wu, Song
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [29] Artificial neural networks applied to the in vitro in vivo correlation of an extended-release formulation: Initial trials and experience
    Dowell, JA
    Hussain, A
    Devane, J
    Young, D
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) : 154 - 160
  • [30] Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations
    Tajiri, Shinichiro
    Kanamaru, Taro
    Makoto, Kamada
    Konno, Tsutomu
    Nakagami, Hiroaki
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 383 (1-2) : 99 - 105